Get the Stockscreener App
15.75
7.13%
-1.21
After Hours:
15.51
-0.24
-1.52%
Monopar Therapeutics Inc stock is traded at $15.75, with a volume of 187.81K.
It is down -7.13% in the last 24 hours and up +241.65% over the past month.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicin for the treatment of soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.
See More
Previous Close:
$16.96
Open:
$16.31
24h Volume:
187.81K
Relative Volume:
0.15
Market Cap:
$62.82M
Revenue:
-
Net Income/Loss:
$-7.12M
P/E Ratio:
-20.45
EPS:
-0.77
Net Cash Flow:
$-6.82M
1W Performance:
-2.84%
1M Performance:
+241.65%
6M Performance:
+2,066%
1Y Performance:
+2,988%
1-Day Range:
$15.51
$16.64
1-Week Range:
$12.55
$18.20
52-Week Range:
$0.2739
$38.50
Monopar Therapeutics Inc Stock (MNPR) Company Profile
Name
Monopar Therapeutics Inc
Sector
Industry
Phone
(847) 388-0349
Address
1000 SKOKIE BLVD SUITE 350, WILMETTE
Monopar Therapeutics Inc Stock (MNPR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-28-21 | Initiated | ROTH Capital | Buy |
Monopar Therapeutics Inc Stock (MNPR) Latest News
RA Capital Management, L.P. Acquires New Stake in Monopar Therap - GuruFocus.com
Insider Purchase: CFO Karthik Radhakrishnan Acquires Shares of M - GuruFocus.com
Monopar Therapeutics Closes $19.2 Million Stock Offering - TipRanks
Monopar Therapeutics Inc. Announces Closing of $19.2 Million Public Offering of Common Stock - ForexTV.com
Monopar Therapeutics drops 16%, prices $19M offering at $16.25 per share - MSN
(MNPR) Investment Analysis - Stock Traders Daily
Monopar Therapeutics announces public stock offering By Investing.com - Investing.com Nigeria
Monopar Therapeutics Inc. Announces Pricing of $19.2 Million Public Offering of Common Stock - The Manila Times
Monopar Therapeutics Inc. Announces Pricing of $19.2 Million Public Offering of Common Stock - GlobeNewswire Inc.
Monopar Therapeutics announces public stock offering - Investing.com
Monopar Therapeutics Inc. Announces Proposed Public Offering of Common Stock - The Manila Times
Monopar Therapeutics Inc. (NASDAQ:MNPR) Sees Significant Drop in Short Interest - MarketBeat
Monopar Therapeutics Inc.'s (NASDAQ:MNPR) biggest owners are retail investors who got richer after stock soared 208% last week - Simply Wall St
Individual investors are Monopar Therapeutics Inc.'s (NASDAQ:MNPR) biggest owners and were rewarded after market cap rose by US$40m last week - Yahoo Finance
Monopar Therapeutics Skyrockets 400% on Licensing Deal - MSN
Wilmette startup's stock soars as it buys back the drug its founder made from Big Pharma - Crain's Chicago Business
Monopar Therapeutics (NASDAQ:MNPR) Shares Gap DownHere's What Happened - MarketBeat
What's Going On With Monopar Therapeutics Shares Friday? - Benzinga
Monopar Therapeutics Secures License for Wilson Disease Treatment - Yahoo Finance
Why Deckers Outdoor Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket - Benzinga
Monopar Therapeutics Skyrockets 400% On Licensing Deal - Barchart
MNPR,NTLA,CPRI,WDC,TSLA: Top 5 Trending Stocks TodayMonopar Therapeutics (NASDAQ:MNPR), Capri Holdings (NYSE:CPRI) - Benzinga
Monopar Therapeutics Inc. has entered into an agreement to acquire worldwide license to ALXN-18 from Alexion Pharmaceuticals, Inc. - Marketscreener.com
Health Care Down Amid Mixed Drug Developments -- Health Care Roundup - MarketWatch
U.S. stocks mixed at close of trade; Dow Jones Industrial Average down 0.33% - MSN
Viking Therapeutics stock soars on heels of Q3 beat - Yahoo Finance
Monopar Therapeutics (NASDAQ:MNPR) Hits New 52-Week HighStill a Buy? - MarketBeat
Monopar secures global license for Wilson disease drug - Investing.com
Monopar retrieves Wilson disease candidate from AstraZeneca's scrap heap - Fierce Biotech
CDC And Prevention Advisory Panel Backs Expanded Use Of Pfizer And Merck's Pneumococcal Vaccines - Yahoo Finance
Monopar Therapeutics, Energy Vault Holdings, FREYR Battery: 3 Stocks Retailers Are Most Bullish Thursday Afternoon - Barchart
Why Is Monopar Therapeutics Stock Surging Over 400% On Thursday?AstraZeneca (NASDAQ:AZN), Monopar Therapeutics (NASDAQ:MNPR) - Benzinga
Monopar Up 450%Were You On Board? - RTTNews
Monopar Therapeutics (MNPR) Shares Surge on Partnership with Ale - GuruFocus.com
Monopar (MNPR) Experiences Stock Boost After An Agreement - Stocks Telegraph
Monopar Shares Surge on AstraZeneca Licensing Deal -- Update - MarketWatch
Monopar stock soars to 52-week high, hits $8.75 - Investing.com
Monopar secures global license for Wilson disease drug By Investing.com - Investing.com South Africa
Monopar Shares Rise on AstraZeneca Licensing Deal - Marketscreener.com
Monopar stock climbs as it takes over Wilson disease drug candidate (NASDAQ:MNPR) - Seeking Alpha
Monopar Therapeutics Inc Announces Agreement with Alexion, AstraZeneca Rare Disease for Late-Stage Wilson Disease Drug Candidate - Marketscreener.com
Oral Mucositis Market Forecasted to Surge in Coming Years, 2024-2034 Analysis by DelveInsight | Swedish Orphan Biovitrum, Galera Therapeutics, EpicentRx, Galera Therapeutics, Inc., Soligenix - Barchart
Monopar Therapeutics Unveils Promising Radiopharmaceutical Data - TipRanks
Monopar Presents Encouraging Human Clinical Dosimetry Data on its uPAR Program at EANM 2024 - The Manila Times
(MNPR) Trading Advice - Stock Traders Daily
Monopar Therapeutics Expands Portfolio with New Patent Filing - Yahoo Finance
Monopar Expands Radiopharma Intellectual Property Portfolio with Patent Filing on New Compounds and Linkers - The Manila Times
Monopar Therapeutics Inc. (NASDAQ:MNPR) Sees Large Decrease in Short Interest - MarketBeat
Monopar Therapeutics Launches Phase 1a uPAR-Targeted Cancer Trial - Yahoo Finance
Monopar Initiates Clinical Trial of Novel uPAR-Targeted Radiopharmaceutical Therapy in Advanced Cancers - The Manila Times
Monopar Presents Data Showcasing the Appeal of uPAR as a - GlobeNewswire
Monopar Therapeutics Inc Stock (MNPR) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.02%
0.47%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):